J&J Slammed With Costliest Talc Verdict Yet; California Plaintiff Awarded $417M
This article was originally published in The Rose Sheet
California could emerge as the new hub for talc litigation following a Los Angeles jury verdict awarding $417m in damages to a terminally ill plaintiff who linked her ovarian cancer to longtime use of J&J's talcum powder products.
You may also be interested in...
A California jury sided with J&J Nov. 16 in the first trial over whether alleged asbestos in the firm's talcum powders caused plaintiff's mesothelioma. The verdict could help check what threatens to be a new field of litigation against J&J for alleged talc dangers, and the firm also is gaining momentum in its defense against ovarian cancer claims.
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
A judge in the Missouri state court where J&J has suffered a series of hefty losses declared a mistrial June 19 in the latest talc-cancer case to be heard by jurors. The decision came two days after a US Supreme Court decision that also could trigger reversals of costly J&J verdicts currently under appeal.